RNA Interference for Drug R&D: Applications, Alliances, Companies and WW Market to 2011

Table of Contents

1.RNAi Market & Business Models

• Overview of RNA Interference
  • Double Stranded RNA (dsRNA)
  • Small interfering RNA (siRNA)
  • Short Hairpin RNA (shRNA)
  • DNA-directed RNAi (ddRNAi)
  • MicroRNA (miRNA)
• The RNAi Market & Key Customer Applications
  • The WW RNAi Market
  • RNAi Tools for Research, Drug Discovery &
    • Development
    • As Tools for Basic Research
    • As Tools for Drug Discovery
    • As Tools for Drug Development
• RNAi-as-Drugs (Therapeutics)
• Competitive Market
  • Market Map of Major Players
  • Major Players by Focus Segment and Product Strategy
  • Research Findings & Analysis
    • Market Leaders
    • RNAi Moves Upstream on the Drug R&D Path
    • Technology Big Picture
    • Business Model & Product Development Strategies

2.M&A and Alliance Activities

• Analysis of RNAi M&As and Alliances, 2005 to July-2007
• RNAi Alliances and M&As, 2005 to June-2007
• Intellectual Property and Regulatory Approval
  • Intellectual Property
  • Regulatory Approval
• Findings: Companies to Watch for Future R&D
  • RNAi Technology Companies on the Move
  • Big Pharma is Involved in RNAi

3.Market Forecast and Trends

• The WW RNA Interference (RNAi) Market Size 2006-2011
• WW RNAi Market by Segments
  • RNAi Market By WW Regions
  • RNAi Market By Application Segments
    • RNAi in Basic Research
    • RNAi in Drug Discovery
    • RNAi in Drug Development
    • RNAi Therapeutics
  • RNAi Application Segment Market Shares, 2007 & 2011
  • RNAi Market By Major Disease Segments
    • Cancer
    • Infections
    • Metabolic
    • Eye disease
    • CNS
    • Respiratory
    • Inflammation
    • Bone Diseases
    • Blood Disease
    • Cardiovascular
    • Diagnostics, Skin Conditions and Others
  • Major Disease Segment Market Shares (%), 2007 & 2011
  • RNAi Market By Product Segments
    • RNAi Reagents & Related Services
    • RNAi Delivery Tools & Devices
    • Assay Systems
    • Cell Lines & Related
    • Discovery Techs, Services & Drugs
    • Genomewide RNAi HT/ HC Screening Tools
  • RNAi Product Segment Market Shares (%), 2007 & 2011
• Key Trends/ Future Directions
  • Big Pharma Starting to Get Involved in RNAi
  • Advances Made in Dealing With Off-target Effects
  • Growing Knowledge About microRNAs
  • Direct Delivery of RNAi-based Drugs
  • Systemic Delivery of RNAi Drugs
  • RNAi Future Direction Timeline

4.Selected Companies Working in RNAi

• Alnylam Pharmaceuticals, Inc.
• Ambion, Inc.
• Avalon Pharmaceuticals, Inc.
• Benitec, Ltd.
• Cenix Bioscience GmbH
• CytRx Corporation
• Dharmacon, Inc.
• Integrated DNA Technologies, Inc. (IDT)
• Intradigm Corporation
• Intronn, Inc.
• Invitrogen Corporation
• Lentigen Corporation
• Mirus Bio Corporation
• Nastech Pharmaceutical Company Inc.
• Open Biosystems
• Opko Health, Inc.
• Panomics, Inc.
• RNAx GmbH
• Sirna Therapeutics, Inc.
• Targeted Genetics Corporation

5.Findings and Suggestions

• Review of Findings and Key Trends
  • RNAi Technology
  • Competitive Landscape
  • M&As and Alliances
  • Patents
  • Market Assessment
• Recommendations to Capture Opportunities
• Products Needed by RNAi Users in R&D
• Future Market Prospects

6.Appendix

• RNAi Glossary
• Company Contacts
• About Takeda Pacific
• About the Authors

List of Tables

• Table 1. Diseases Targeted by Direct Delivery of RNAi Drugs
• Table 2. Diseases Targeted by Systemic Delivery of RNAi Drugs
• Table 3. Major Players in the RNAi Market
• Table 4. Major Players by Focus Segment and Product Strategy
• Table 5. Summary of RNAi M&As and Alliances, 2005 to July-2007
• Table 6. M&As and Alliances, Jan-July/ 2007
• Table 7. M&As and Alliances, 2006
• Table 8. M&As and Alliances, 2005
• Table 9. RNAi Related Patent Applications (US), 2002-1H2007
• Table 10. Key Patents for RNAi Reagents and Drugs
• Table 11. RNAi Therapeutics In /(or Near) Clinical Trials
• Table 12. Top RNAi Alliance Players: RNAi Technology Companies
• Table 13. Top RNAi Alliance Players: Big Pharmas
• Table 14. WW RNAi Market Size By Total Revenues ($M), 2006-2011
• Table 15. WW RNAi Market By WW Regions and Revenues, 2006-2011
• Table 16. WW Regions Market Shares (%), 2007 & 2011
• Table 17. US RNAi Market By Application Segment Revenues ($M), 2006-2011
• Table 18. Application Segment Market Shares (%), 2007 & 2011
• Table 19. RNAi Market By Major Disease Segments, Revenues ($M), 2006-2011
• Table 20. Major Disease Segment Market Shares (%), 2007 & 2011
• Table 21. RNAi Market By Product Segments, Revenues ($M), 2006-2011
• Table 22. Product Segment Market Shares (%), 2007 & 2011
• Table 23. RNAi R&D Unmet Needs - Selected Opportunity Matrix

List of Illustrations

• Figure 1. Timeline for Key RNAi Technology Developments
• Figure 2. Central Theme of Modern Biology, DNA encodes for Proteins
• Figure 3. The RNAi Process with dsRNA, shRNA, siRNA and RISC
• Figure 4. RNAi R&D Market by Major Applications
• Figure 5. RNAi Related Patent Applications (US), 2002-1H2007
• Figure 6. New Drug Approval Timeline and Roadmap
• Figure 7. WW RNAi Market Size By Total Revenues ($M), 2006-2011
• Figure 8. WW RNAi Market By WW Regions and Revenues, 2006-2011
• Figure 9. WW RNAi Market By WW Regions and Shares, 2007 & 2011
• Figure 10. WW RNAi Market By Application Segment Revenues, 2006-2011
• Figure 11. RNAi Application Segment Market Shares (%), 2007 & 2011
• Figure 12. RNAi Market By Major Disease Segments, Revenues ($M), 2006-2011
• Figure 13. Major Disease Segment Market Shares (%), 2007 & 2011
• Figure 14. RNAi Market By Product Segments, Revenues ($M), 2006-2011
• Figure 15. Product Segment Market Shares (%), 2007 & 2011
• Figure 16. RNAi Future Direction Timeline to 2011